Intravenous immunoglobulin-associated acute renal failure: Case series and literature review

Pharmacotherapy

Volumn 25, Issue 6, 2005, Pages 886-892

  Itkin, Yelena M ^a   Trujillo, Toby C ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Acute renal failure; Adverse effects; Intravenous immunoglobulin; IVIg; Sugar excipients

Indexed keywords

ATENOLOL; CALCIUM; CALCIUM ACETATE; CREATINE; CYCLOPHOSPHAMIDE; DOCUSATE SODIUM; ESOMEPRAZOLE; EXCIPIENT; FOLIC ACID; FUROSEMIDE; GABAPENTIN; GLUCOSE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; HYDROXYZINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IRBESARTAN; LEVOTHYROXINE; LORAZEPAM; MALTOSE; MANNITOL; MORPHINE; MULTIVITAMIN; NITROGEN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PANGLOBULIN; POLYSTYRENESULFONATE SODIUM; PREDNISONE; SORBITOL; SUCROSE; SUGAR; TORASEMIDE; TRIAMCINOLONE; UREA; VENLAFAXINE; VERAPAMIL; VITAMIN D; WARFARIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANAMNESIS; ANURIA; ARTHRALGIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BACKACHE; CASE REPORT; CHILL; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG FATALITY; DRUG FORMULATION; DRUG INDICATION; DRUG INFUSION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; HEMATOLOGIC DISEASE; HEMATURIA; HEMOLYSIS; HIGH RISK PATIENT; HIP; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; KIDNEY FAILURE; MALE; NAUSEA; NEPHROSIS; NEUROLOGIC DISEASE; OLIGURIA; PAIN; PANCYTOPENIA; POLYMYOSITIS; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; REVIEW; RHEUMATIC DISEASE; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC HYPERTENSION; THORAX PAIN; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; SUCROSE;

EID: 19444377840     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.6.886     Document Type: Review

References (24)

1. Ashan N, Wiegand L, Abendroth C, Manning E. Acute renal failure following immunoglobulin therapy. Am J Nephrol 1996;16:532-6.
2. Cantu TG, Hoehn-Saric EW, Burgess KM, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995;25(2):228-34.
3. Simon HU, Space PJ. IVIG mechanism of action. Allergy 2003;58(7):543-55.
4. ASHP Commission on Therapeutics. American Society of Health-System Pharmacists therapeutic guidelines for intravenous immune globulin. Clin Pharm 1992;11:117-36.
5. Haskin JA, Warner DJ, Blank DU. Acute renal failure after large dose of intravenous immune globulin. Ann Pharm 1999;33(7-8):800-3.
6. Epstein JS, Zoon KC. Important drug warning. Rockville, MD: Food and Drug Administration, Center for Biologies Evaluation and Research, September 24, 1999. Available from www.fda.gov/medwatch/SAFETY/1998/igiv.htm. Accessed April 14, 2005.
7. Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol 1997;8:1788-94.
8. Rault R, Piraino B, Johnston J, et al. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991;36:83-6.
9. Pasatiempo A, Kroser J, Ruducek M, et al. Acute renal failure after intravenous immunoglobulin therapy. J Rheum 1994;21:347-9.
10. Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high dose of immunoglobulin therapy containing sucrose (but not glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis 1996;28:451-3.
11. Gupta NI, Nissel-Horowitz S, Patel D, et al. Intravenous gammaglobulin-associaled acute renal failure. Am. J Hematol 2001;66:151-2.
12. Michail S, Nakopoulou L, Stavrianopoulos I, et al. Acute renal failure associated with immunoglobulin administration. Nephrol Dial Transplant 1997;12:1497-9.
13. Ruggeri M, Castaman G, De Nardi G, et al. Acute renal failure after high-dose intravenous immune globulin in a patient with idiopathic thrombocytopenic purpura. Haemaologiga 1993;78:338-9.
14. Stahl M, Schifferli JA. The renal risks of high-dose intravenous immunoglobulin treatment. Nephrol Dial Transplant 1998;13:2182-4.
15. Ellie E, Combe C, Feffer X, et al. High-dose intravenous immune globulin and acute renal failure. N Engl J Med 1992;327(14):1032-3.
16. Winward DB, Brophy MT. Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. Pharmacotherapy 1995;15(6):765-72.
17. Ashan N, Palmer BF, Wheeler D, et al. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med 1994;154:1985-7.
18. Schifferli J, Leski M, Favre H, et al. High-dose intravenous IgG treatment and renal failure. Lancet 1991;337:457-8.
19. Arunabh S, Kumar G, Avila V. Acute renal failure induced by intravenous immune globulin. Am Fam Phys 1996;53(3):862-5.
20. Kobosko J, Nicol P. Renal toxicity of intravenous immunoglobulin [letter]. J Clin Nephrol 1992;37:216-17.
21. Phillips AO. Renal failure and intravenous immunoglobulin [letter]. J Clin Nephrol 1992;37:217.
22. Rigdon R, Cardwell E. Renal lesions after the intravenous injection of a hypertonic solution of sucrose. Arch Intern Med 1942;69:670-90.
23. Anderson W, Betheca W. Renal lesions after administration of hypertonic solution of sucrose. JAMA 1940;114(20):1983-7.
24. Janigan DT, Santamaria A. A histochemical study of swelling and vacuolation of proximal tubular cells in sucrose nephrosis in the rat. Am J Pathol 1961;39(2):175-92.